Medication info
Diroltan 160mg (Valsartan)

Diroltan 160mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
IYOUN Pharmaceuticals Co., Ltd.
Appearance
Oval film-coated tablet with an orange color that has a gray tint
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200811619 · Notified 2008.12.16 · Insurance code 658602540

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended oral dose, regardless of sex or race, is 80 mg of valsartan once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose must not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, which may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose should then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary in patients with creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
IYOUN Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication is used to reduce essential hypertension, heart failure, and the risk of mortality after myocardial infarction. It is particularly effective in heart failure patients who are intolerant to ACE inhibitors and reduces the risk of mortality after myocardial infarction in patients with left ventricular dysfunction. Therefore, it is used as a medication that helps improve health by assisting in blood pressure control and enhancing heart function.

How to take

Adult dose

(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended oral dose, regardless of sex or race, is 80 mg of valsartan once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be added. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose must not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, which may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose should then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary in patients with creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication may cause severe harm to the fetus and newborn if taken during pregnancy, especially in the 2nd and 3rd trimesters, so it should be discontinued immediately if pregnancy is confirmed. It should not be used by people with certain conditions. For example, individuals allergic to this medication or its ingredients, pregnant or breastfeeding women, individuals with severe liver or kidney disease, and patients with a history of certain vascular edema should not use it. Elderly patients, those with hyperkalemia, patients with compromised liver function, and patients with heart valve diseases or related issues should use this medication cautiously, with careful monitoring of their condition before and after administration. While taking this medication, blood pressure may drop suddenly, so if symptoms such as dizziness or fainting occur, consult a healthcare professional immediately. Patients with poor kidney function, heart failure, or undergoing dialysis should regularly check their kidney function and electrolyte levels while taking this medication. This medication can increase potassium levels, so caution should be exercised when taken with potassium supplements or potassium-sparing diuretics. Additionally, there may be interactions when taken with other antihypertensive medications, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs), so it is important to consult a healthcare professional. This medication is not recommended for use in children and adolescents as its safety and efficacy have not been established. In case of overdose, severe hypotension, decreased consciousness, shock, etc., may occur, so compliance with the recommended dosage is crucial, and if any unusual symptoms arise, emergency care should be sought immediately. Store this medication out of reach of children and do not transfer it to other containers for safety. Finally, while taking this medication, caution is required when driving or operating machinery, as symptoms like dizziness may occur.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Oval film-coated tablet with an orange color that has a gray tint

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.